Jubilant Pharmova Limited has scheduled its 48th Annual General Meeting (AGM) for Wednesday, August 26, 2026, at 11:00 A.M. (IST). The meeting will be conducted via Video Conferencing or Other Audio Visual Means (VC/OAVM) to transact business including the approval of financial statements for the fiscal year ended March 31, 2026. The most material outcome for shareholders is the proposed dividend payout, which carries significant tax implications requiring proactive documentation submission.

The Board of Directors, in its meeting held on May 22, 2026, recommended a dividend of ₹5 (i.e., 500%) per Equity Share of face value Re. 1 each. This recommendation is subject to final approval by members at the upcoming AGM. The dividend will be paid to shareholders holding equity shares in either electronic or physical form as on the record date, July 24, 2026. Upon declaration, the dividend will be taxable in the hands of shareholders in FY 2026-27 (Assessment Year 2027-28).

Compliance with tax regulations requires shareholders to submit specific documents to determine applicable Tax Deducted at Source (TDS) rates. Pursuant to the Income-tax Act, 2025, the company will withhold taxes at prescribed rates based on residential status and submitted documentation. Executed documents must reach the company on or before August 14, 2026. Shareholders may send these via email to investors@jubl.com or by post to the Corporate Office at Plot 1A, Sector 16A, Noida-201301. Those sending documents via email are also required to forward original executed copies to the corporate office.

The company is providing remote e-voting facilities for all resolutions set out in the AGM notice. Members can also vote through the e-voting system during the AGM session. Detailed procedures for casting votes are provided in the official notice. Attendance via VC/OAVM will be reckoned for quorum purposes under Section 103 of the Companies Act, 2013.

Key Dates and Details

Shareholders whose email addresses are not registered with the company, Depository Participants (DPs), or Registrar and Transfer Agent must register their details to receive the Annual Report electronically. Physical shareholders should email their Folio No., name, scanned share certificate, PAN, and Aadhaar to investors@jubl.com or rta@alankit.com . Demat holders must provide DPID-CLID, name, client master statement, PAN, and Aadhaar. Failure to register bank details may delay dividend receipt; demat holders should contact their DPs, while physical holders should email the investor relations team.

In accordance with Regulation 36(1)(b) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the company will send a letter with web-links to the Annual Report to members without registered emails. The notice and annual report will also be available on the company’s website and stock exchange portals. Newspaper advertisements were published on July 29, 2026, in Financial Express and Hindustan & Jansatta.

Jubilant Pharmova Limited has initiated a postal ballot process to seek shareholder approval for the re-appointment of Mr. Priyavrat Bhartia and Mr. Arjun Shanker Bhartia as Managing Director and Joint Managing Director, respectively. The re-appointments are proposed for a period of three years effective from June 1, 2026, to May 31, 2029. The resolutions require approval as the remuneration payable may exceed five per cent of the net profits, and aggregate remuneration to all directors may exceed ten per cent of net profits.

The remote e-voting period commenced on July 19, 2026, at 9:00 A.M. (IST) and will conclude on August 17, 2026, at 5:00 P.M. (IST). Shareholders whose names appear in the Register of Members or the list of Beneficial Owners as on the cut-off date of July 10, 2026, are entitled to vote. The Board appointed Mr. Rupinder Singh Bhatia, Practicing Company Secretary, as the Scrutinizer for the process. Physical copies of the postal ballot notice are not being dispatched; communication is exclusively through the remote e-voting system.

Re-appointment Details

The Board approved the re-appointments at its meeting held on May 22, 2026. Mr. Priyavrat Bhartia, aged 49, has been associated with the Board since May 2017 and has served as Managing Director since June 1, 2023. Mr. Arjun Shanker Bhartia, aged 39, has been on the Board since May 2017 and was re-designated as Joint Managing Director effective June 1, 2023. The terms include a salary and perquisites of up to ₹7,50,00,000 per annum for each director.

Financial Performance

The explanatory statement provided the financial performance of the Company for the financial year 2025-26. The standalone profit after tax was reported at ₹632 million, while the consolidated profit after tax stood at ₹3,975 million.

The notice states that during FY 2025-26, the Company transferred its Active Pharmaceutical Ingredients (API) business to a wholly owned subsidiary, classifying it as a discontinued operation in standalone financial statements. This resulted in inadequate profits from continuing operations at the standalone level, though the consolidated financial performance was not adversely impacted.